Publication Name	World Journal of Clinical Cases
Manuscript ID	90878
Country	China

Received	2023-12-20 10:01
Peer-Review Started	2023-12-20 10:01
To Make the First Decision
Return for Revision	2024-01-08 10:56
Revised	2024-01-22 09:41
Second Decision	2024-02-28 02:47
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-02-28 08:21
Articles in Press	2024-02-28 08:21
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-03-18 06:56
Publish the Manuscript Online	2024-03-25 08:14

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Case Report
Article Title	Upadacitinib for refractory ulcerative colitis with primary nonresponse to infliximab and vedolizumab: A case report
Manuscript Source	Unsolicited Manuscript
All Author List	Xuan Xu, Jing-Wen Jiang, Bing-Yun Lu and Xia-Xi Li
Funding Agency and Grant Number	Funding Agency Grant Number Shenzhen Science and Technology Program JCYJ20220530154013031 Guangdong Province Health and Health Appropriate Technology Promotion Project 2023385 Guangdong Province Grassroots Science Popularization Action Plan 20240205
Corresponding Author	Xia-Xi Li, PhD, Chief Doctor, Department of Gastroenterology, Shenzhen Hospital of Southern Medical University, No. 1333 Xinhu Road, Shenzhen 518100, Guangdong Province, China. xiaxi_li@foxmail.com
Key Words	Upadacitinib; Refractory ulcerative colitis; Primary nonresponse; Infliximab; Vedolizumab; Case report
Core Tip	Ulcerative colitis (UC) is a major type of inflammatory bowel disease. Many patients do not respond well to the current therapies. We report the case of a patient diagnosed with refractory UC, with primary nonresponse to infliximab and vedolizumab. The patient experienced recurrent symptoms after receiving mesalazine, prednisone, azathioprine, infliximab, and vedolizumab for more than four years. After optimising the upadacitinib treatment, UC remission was achieved. Our report suggests that the small-molecule upadacitinib may be a new treatment option that deserves to be reported and studied.
Publish Date	2024-03-25 08:14
Citation	Xu X, Jiang JW, Lu BY, Li XX. Upadacitinib for refractory ulcerative colitis with primary nonresponse to infliximab and vedolizumab: A case report. World J Clin Cases 2024; 12(9): 1685-1690
URL	https://www.wjgnet.com/2307-8960/full/v12/i9/1685.htm
DOI	https://dx.doi.org/10.12998/wjcc.v12.i9.1685

Full Article (PDF)	WJCC-12-1685-with-cover.pdf
CARE Checklist–2016	90878-CARE Checklist (2016).pdf
Manuscript File	90878_Auto_Edited-YJP.docx
Answering Reviewers	90878-Answering reviewers.pdf
Audio Core Tip	90878-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	90878-Conflict-of-interest statement.pdf
Copyright License Agreement	90878-Copyright license agreement.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	90878-Grant application form(s).pdf
Signed Consent for Treatment Form(s) or Document(s)	90878-Informed consent statement.pdf
Non-Native Speakers of English Editing Certificate	90878-Language certificate.pdf
Peer-review Report	90878-Peer-review(s).pdf
Scientific Misconduct Check	90878-Bing-Zhang L-2.png
Scientific Editor Work List	90878-Scientific editor work list.pdf
CrossCheck Report	90878-CrossCheck report.pdf
CrossCheck Report	90878-CrossCheck.png